Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Neurology, Multiple Sclerosis |
| Therapuetic Areas: | Neurology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2019 |
| Start Date: | February 8, 2019 |
| End Date: | July 2019 |
| Contact: | Trial Transparency email recommended (Toll free number for US & Canada) |
| Email: | Contact-US@sanofi.com |
| Phone: | 800-633-1610 |
Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment
Primary Objective:
To assess in a new cohort of patients pre-identified candidate single nucleotide polymorphism
(SNPs) associated to the development of immune thrombocytopenic purpura (ITP) after LEMTRADA
treatment in relapsing multiple sclerosis (RMS) patients.
To assess in a new cohort of patients pre-identified candidate single nucleotide polymorphism
(SNPs) associated to the development of immune thrombocytopenic purpura (ITP) after LEMTRADA
treatment in relapsing multiple sclerosis (RMS) patients.
One day to 1 month, as screening and inclusion visit can be performed the same day or on
separate days with a maximum timeframe of 1 month apart.
separate days with a maximum timeframe of 1 month apart.
Inclusion criteria :
- Male and female adult patients who have been treated with LEMTRADA, as per label, with
development of immune thrombocytopenic purpura (ITP) subsequent to treatment. Patients
do not need to be currently on LEMTRADA treatment.
- Patients who have signed the study informed consent form (ICF).
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
We found this trial at
1
site
Click here to add this to my saved trials
